Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical focuses on developing treatments for rare genetic diseases globally. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company also has several product candidates in development, such as DTX401, DTX301, UX143, GTX-102, UX111, UX701, and UX053. Ultragenyx collaborates with multiple organizations, including Kyowa Kirin Co., Ltd. and Regeneron. The company was incorporated in 2010 and is headquartered in Novato, California. It focuses on identifying, acquiring, developing, and commercializing novel products for rare diseases.
Overview
Strengths
- Creates economic value: ROIC of 100.0% against a cost of capital (WACC) of 6.4%, a spread of 93.6 percentage points.
- Consistent growth: revenue has compounded at 19.9% a year over 5 years, rising every year.
- ROIC of 100.0% beats 93% of its 128 Biotechnology peers (median 0.0%).
Weaknesses
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Shareholder dilution: the share count has grown by 11.2% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
- Unstable profitability: operating margin ranged from -179% to -79% over the last 6 years, with operating losses in 6 of them.
Key Financial Data